Fecal microbiota transplantation in childhood: past, present, and future

Xu Gu,Zhao-Hong Chen,Shu-Cheng Zhang

DOI: https://doi.org/10.1007/s12519-022-00655-w

2022-12-10

World Journal of Pediatrics

Abstract:Fecal microbiota transplantation (FMT) has been well described in the treatment of pediatric diseases; however, the latest updates regarding its use in children are unclear and the concepts involved need to be revisited.

pediatrics

What problem does this paper attempt to address?

Fecal microbiota transplantation: current challenges and future landscapes

Abbas Yadegar,Haggai Bar-Yoseph,Tanya Marie Monaghan,Sepideh Pakpour,Andrea Severino,Ed J. Kuijper,Wiep Klaas Smits,Elisabeth M. Terveer,Sukanya Neupane,Ali Nabavi-Rad,Javad Sadeghi,Giovanni Cammarota,Gianluca Ianiro,Estello Nap-Hill,Dickson Leung,Karen Wong,Dina Kao

DOI: https://doi.org/10.1128/cmr.00060-22

IF: 36.8

2024-05-09

Clinical Microbiology Reviews

Abstract:SUMMARY Given the importance of gut microbial homeostasis in maintaining health, there has been considerable interest in developing innovative therapeutic strategies for restoring gut microbiota. One such approach, fecal microbiota transplantation (FMT), is the main “whole gut microbiome replacement” strategy and has been integrated into clinical practice guidelines for treating recurrent Clostridioides difficile infection (rCDI). Furthermore, the potential application of FMT in other indications such as inflammatory bowel disease (IBD), metabolic syndrome, and solid tumor malignancies is an area of intense interest and active research. However, the complex and variable nature of FMT makes it challenging to address its precise functionality and to assess clinical efficacy and safety in different disease contexts. In this review, we outline clinical applications, efficacy, durability, and safety of FMT and provide a comprehensive assessment of its procedural and administration aspects. The clinical applications of FMT in children and cancer immunotherapy are also described. We focus on data from human studies in IBD in contrast with rCDI to delineate the putative mechanisms of this treatment in IBD as a model, including colonization resistance and functional restoration through bacterial engraftment, modulating effects of virome/phageome, gut metabolome and host interactions, and immunoregulatory actions of FMT. Furthermore, we comprehensively review omics technologies, metagenomic approaches, and bioinformatics pipelines to characterize complex microbial communities and discuss their limitations. FMT regulatory challenges, ethical considerations, and pharmacomicrobiomics are also highlighted to shed light on future development of tailored microbiome-based therapeutics.

microbiology
Faecal microbiota transplantation in children: A systematic review

Ella Lauwers,João Sabino,Ilse Hoffman,Karen van Hoeve

DOI: https://doi.org/10.1111/apa.17167

Abstract:Aim: Novel technologies offer insights into the potential role of the intestinal microbiota in human health and disease. Dysbiosis has been associated with several diseases, and it is thought to play a role in the pathogenesis of different gastrointestinal diseases. Faecal microbiota transplantation (FMT) is emerging as a method to modulate the gastrointestinal microbial ecosystem. While recurrent Clostridioides difficile infection is the recognised FMT indication, exploration of other therapeutic uses is ongoing. Methods: Following PRISMA guidelines, we conducted a systematic review, extracting 583 articles from Embase and PubMed (index date to October 2022). Results: The search yielded 58 studies for full review, with 50 included in the systematic review. Articles were categorised by FMT indication, study design, efficacy, adverse events, donor selection and administration route. FMT appears safe and effective for recurrent Clostridioides difficile infection, although severe adverse events are reported in children. However, there are currently insufficient data to support the use of FMT for other potential therapeutic indications (such as irritable or inflammatory bowel disease or obesity), beside the potential to decolonise multi-drug resistant organisms. Conclusion: This underscores the need for randomised, controlled, prospective cohort studies in children to assess FMT effectiveness in diverse conditions and counteract publication bias.
What nurses need to know about fecal microbiota transplantation: education, assessment, and care for children and young adults

Bennett P Samuel,Teri L Crumb,Mary M Duba

DOI: https://doi.org/10.1016/j.pedn.2014.01.013

Abstract:Fecal microbiota transplantation (FMT) is an emerging experimental therapy for treatment of recurrent Clostridium difficile infection. In the future, FMT has the potential to be a treatment modality in other diseases that involve gut dysbiosis. As use of FMT is likely to expand, pediatric nurses need a clear understanding of FMT to provide appropriate education, assessment, and care for these patients. Pediatric research and clinical nurses are a resource to help children and parents understand the procedure. Important topics include donor screening, patient assessment before, during, and after treatment; routes of administration and positioning; preparation for discharge and followup evaluation.
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

Colleen R. Kelly,Stacy Kahn,Purna Kashyap,Loren Laine,David Rubin,Ashish Atreja,Thomas Moore,Gary Wu

DOI: https://doi.org/10.1053/j.gastro.2015.05.008

IF: 29.4

2015-07-01

Gastroenterology

Abstract:The community of microorganisms within the human gut (or microbiota) is critical to health and functions with a level of complexity comparable to that of an organ system. Alterations of this ecology (or dysbiosis) have been implicated in a number of disease states, and the prototypical example is Clostridium difficile infection (CDI). Fecal microbiota transplantation (FMT) has been demonstrated to durably alter the gut microbiota of the recipient and has shown efficacy in the treatment of patients with recurrent CDI. There is hope that FMT may eventually prove beneficial for the treatment of other diseases associated with alterations in gut microbiota, such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome, to name a few. Although the basic principles that underlie the mechanisms by which FMT shows therapeutic efficacy in CDI are becoming apparent, further research is needed to understand the possible role of FMT in these other conditions. Although relatively simple to perform, questions regarding both short-term and long-term safety as well as the complex and rapidly evolving regulatory landscape has limited widespread use. Future work will focus on establishing best practices and more robust safety data than exist currently, as well as refining FMT beyond current "whole-stool" transplants to increase safety and tolerability. Encapsulated formulations, full-spectrum stool-based products, and defined microbial consortia are all in the immediate future.

gastroenterology & hepatology
Fecal Microbiota Transplantation: An Update on Clinical Practice

Kyeong Ok Kim,Michael Gluck

DOI: https://doi.org/10.5946/ce.2019.009

2019-03-31

Clinical Endoscopy

Abstract:Fecal microbiota transplantation (FMT) is an infusion in the colon, or the delivery through the upper gastrointestinal tract, of stool from a healthy donor to a recipient with a disease believed to be related to an unhealthy gut microbiome. FMT has been successfully used to treat recurrent Clostridium difficile infection (rCDI). The short-term success of FMT in rCDI has led to investigations of its application to other gastrointestinal disorders and extra-intestinal diseases with presumed gut dysbiosis. Despite the promising results of FMT in these conditions, several barriers remain, including determining the characteristics of a healthy microbiome, ensuring the safety of the recipient with respect to long-term outcomes, adequate monitoring of the recipient of fecal material, achieving high-quality control, and maintaining reasonable costs. For these reasons, establishing uniform protocols for stool preparation, finding the best modes of FMT administration, maintaining large databases of donors and recipients, and assuring that oral ingestion is equivalent to the more widely accepted colonoscopic infusion are issues that need to be addressed.
Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives

Hyun Ho Choi,Young-Seok Cho

DOI: https://doi.org/10.5946/ce.2015.117

2016-05-30

Clinical Endoscopy

Abstract:Fecal microbiota transplantation (FMT) is the infusion of liquid filtrate feces from a healthy donor into the gut of a recipient to cure a specific disease. A fecal suspension can be administered by nasogastric or nasoduodenal tube, colonoscope, enema, or capsule. The high success rate and safety in the short term reported for recurrent Clostridium difficile infection has elevated FMT as an emerging treatment for a wide range of disorders, including Parkinson's disease, fibromyalgia, chronic fatigue syndrome, myoclonus dystopia, multiple sclerosis, obesity, insulin resistance, metabolic syndrome, and autism. There are many unanswered questions regarding FMT, including donor selection and screening, standardized protocols, long-term safety, and regulatory issues. This article reviews the efficacy and safety of FMT used in treating a variety of diseases, methodology, criteria for donor selection and screening, and various concerns regarding FMT.
Fecal microbiota transplantation: in perspective

Shaan Gupta,Emma Allen-Vercoe,Elaine O. Petrof

DOI: https://doi.org/10.1177/1756283x15607414

2015-10-11

Therapeutic Advances in Gastroenterology

Abstract:There has been increasing interest in understanding the role of the human gut microbiome to elucidate the therapeutic potential of its manipulation. Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient’s gut microbial composition and confer a health benefit. FMT has been used to successfully treat recurrent Clostridium difficile infection. There are preliminary indications to suggest that it may also carry therapeutic potential for other conditions such as inflammatory bowel disease, obesity, metabolic syndrome, and functional gastrointestinal disorders.

gastroenterology & hepatology
An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases

Karen M. J. Waller,Rupert W. Leong,Sudarshan Paramsothy

DOI: https://doi.org/10.1111/jgh.15731

2021-11-12

Journal of Gastroenterology and Hepatology

Abstract:Our understanding of the microbiome and its implications for human health and disease continues to develop. Fecal microbiota transplantation (FMT) is now an established treatment for recurrent Clostridioides difficile infection. There is also increasing evidence for the efficacy of FMT in inducing remission for mild-moderate ulcerative colitis. However, for other indications, data for FMT are limited, with randomized controlled trials rare, typically small and often conflicting. Studies are continuing to explore the role of FMT for many other conditions, including Crohn's disease, functional gut disorders, metabolic syndrome, modulating responses to chemotherapy, eradication of multidrug resistant organisms, and the gut-brain axis. In light of safety, logistical, and regulatory challenges, there is a move to standardized products including narrow spectrum consortia. However, the mechanisms underpinning FMT remain incompletely understood, including the role of non-bacterial components, which may limit success of novel microbial approaches.

gastroenterology & hepatology
Fecal microbiota transplantation and emerging applications

Thomas J. Borody,Alexander Khoruts

DOI: https://doi.org/10.1038/nrgastro.2011.244

2011-12-20

Abstract:The gut microbiota is now widely recognized to have a central role in human health and disease, and can be manipulated to improve an individual's health. Fecal microbiota transplantation (FMT), as outlined in this Review, is one such approach to resolve dysbiosis of the gut microbiota and has therapeutic potential in a range of gastrointestinal diseases. The authors provide a broad overview of FMT and a timely update on the latest advances.

gastroenterology & hepatology
Clinical Application and Potential of Fecal Microbiota Transplantation

R.E. Ooijevaar,E.M. Terveer,H.W. Verspaget,E.J. Kuijper,J.J. Keller

DOI: https://doi.org/10.1146/annurev-med-111717-122956

2019-01-27

Annual Review of Medicine

Abstract:Fecal microbiota transplantation (FMT) is a well-established treatment for recurrent Clostridioides difficile infection. FMT has become a more readily available and useful new treatment option as a result of stool banks. The current state of knowledge indicates that dysbiosis of the gut microbiota is implicated in several disorders in addition to C. difficile infection. Randomized controlled studies have shown FMT to be somewhat effective in treating ulcerative colitis, irritable bowel syndrome, and hepatic encephalopathy. In addition, FMT has been beneficial in treating several other conditions, such as the eradication of multidrug-resistant organisms and graft-versus-host disease. We expect that FMT will soon be implemented as a treatment strategy for several new indications, although further studies are needed.

medicine, research & experimental
Long-term safety and efficacy of fecal microbiota transplantation in 74 children: A single-center retrospective study

Biao Zou,Sheng-Xuan Liu,Xue-Song Li,Jia-Yi He,Chen Dong,Meng-Ling Ruan,Lei Xu,Tao Bai,Zhi-Hua Huang,Sai-Nan Shu

DOI: https://doi.org/10.3389/fped.2022.964154

IF: 3.569

2022-10-12

Frontiers in Pediatrics

Abstract:Background: Fecal microbiota transplantation (FMT) is an effective treatment for intestinal and extra-intestinal disorders. Nonetheless, long-term safety and efficacy remain major challenges for FMT applications. To date, few long-term follow-up studies have been published on FMT in children. Methods: Retrospective reviewed the medical charts of 74 patients who underwent 508 FMT courses between August 2014 and July 2019 at our medical center. All the FMT procedures followed uniform standards. Baseline characteristics pre-FMT and follow-up data were collected at 1, 3, 6, 12, 36, 60, and 84 months after FMT. All potential influencing factors for adverse events (AEs) were analyzed and assessed using regression analyses. Results: A total of 70 (13.7%) short-term AEs occurred in twenty-six patients (35.1%). Most AEs (88.5%) occurred within 2 days post-FMT. A total of 91.4% of the AEs were self-limiting. Ulcerative colitis (UC) and within four times of FMT were associated with a higher rate of AEs ( p = 0.028 and p = 0.021, respectively). The primary clinical remission rate after FMT was as high as 72.9%. Twenty-five children were followed for more than 5 years after FMT. The clinical remission rates gradually decreased over time after FMT. During follow-up, none of the patients developed autoimmune, metabolic, or rheumatologic disorders or tumor-related diseases. However, nine children developed rhinitis, five developed rhinitis, were underweight, and six developed constipation. Conclusions: FMT is a safe and effective treatment for dysbiosis in children. The long-term efficacy of FMT for each disease decreased over time. Moreover, multiple FMTs are recommended 3 months post-FMT for recurrent diseases.

pediatrics
Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in Children

Ying Huang

DOI: https://doi.org/10.3760/cma.j.issn.2095-428x.2017.07.004

2017-01-01

Abstract:Inflammatory bowel disease (IBD) is a group of chronic, relapsing and nonspecific intestinal inflammatory diseases of unknown etiology.More and more evidence indicated that the intestinal microflora might play an important role in the pathogenesis of IBD.Fecal microbiota transplantation (FMT) has been used in intestinal flora imbalance related diseases and achieved favorable results.This article mainly reviewed the application of FMT in the treatment of children with IBD. Key words: Fecal microbiota transplantation; Intestinal microflora; Inflammatory bowel disease; Child
Fecal Microbiota Transplantation: Indications, Methods, and Challenges

Jee Young Lee,Yehwon Kim,Jiyoun Kim,Jiyeun Kate Kim

DOI: https://doi.org/10.1007/s12275-024-00184-3

2024-11-27

The Journal of Microbiology

Abstract:Over the past two decades, as the importance of gut microbiota to human health has become widely known, attempts have been made to treat diseases by correcting dysbiosis of gut microbiota through fecal microbiota transplantation (FMT). Apart from current knowledge of gut microbiota, FMT to treat disease has a long history, from the treatment of food poisoning in the fourth century to the treatment of Clostridioides difficile infections in the twentieth century. In 2013, FMT was recognized as a standard treatment for recurrent C. difficile because it consistently showed high efficacy. Though recurrent C. difficile is the only disease internationally recognized for FMT efficacy, FMT has been tested for other diseases and shown some promising preliminary results. Different FMT methods have been developed using various formulations and administration routes. Despite advances in FMT, some issues remain to be resolved, such as donor screening, manufacturing protocols, and unknown components in the fecal microbiota. In this review, we discuss the mechanisms, clinical indications, methods, and challenges of current FMT. We also discuss the development of alternative therapies to overcome the challenges of FMT.

microbiology
Systematic Review: Faecal Microbiota Transplantation Therapy for Digestive and Nondigestive Disorders in Adults and Children

S. Sha,J. Liang,M. Chen,B. Xu,C. Liang,N. Wei,K. Wu

DOI: https://doi.org/10.1111/apt.12699

IF: 9.524

2014-01-01

Alimentary Pharmacology & Therapeutics

Abstract:BackgroundThere has been growing interest in the use of faecal microbiota transplantation (FMT) for the treatment of gastrointestinal and nongastrointestinal diseases.AimTo review systematically the reported efficacy and safety of FMT in the management of gastrointestinal and nongastrointestinal disorders in adults and children.MethodsThe systematic review followed Cochrane and PRISMA recommendations. Available articles were identified using three electronic databases in addition to hand searching and contacting experts. Inclusion criteria were any reports of FMT therapy written in English.ResultsA total of 844 patients who had undergone FMT were identified from 67 published studies. The most common indications were refractory/relapsing Clostridium difficile infection (CDI) (76.3%) and inflammatory bowel disease (IBD) (13.2%). There has been only one placebo-controlled trial, a successful trial in 43 patients with recurrent CDI. Seven publications report FMT in paediatric patients with a total of 11 treated, 3 with chronic constipation and the remainder with recurrent CDI or ulcerative colitis (UC). 90.7% of patients with refractory/relapsing CDI were cured and 78.4% of patients with IBD were in remission after FMT. FMT therapy could also be effective in treatment of some nongastrointestinal disorders such as chronic fatigue syndrome. The only reported serious adverse event attributed to the therapy was a case of suspected peritonitis.ConclusionsAlthough more controlled trials are needed, faecal microbiota transplantation therapy shows promise in both adults and children with gastrointestinal diseases such as CDI and IBD.
Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Pufang Tan,Xiaogang Li,Jun Shen,Qi Feng

DOI: https://doi.org/10.3389/fphar.2020.574533

IF: 5.6

2020-09-18

Frontiers in Pharmacology

Abstract:Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients.

pharmacology & pharmacy
Fecal microbiota transplantation for the treatment of intestinal and extra‐intestinal diseases: Mechanism basis, clinical application, and potential prospect

Dongxin Yi,Tao Li,Yuji Xiao,Xue Zhang,Qiangqiang Hao,Feng Zhang,Tianming Qiu,Guang Yang,Xiance Sun,Ying Dong,Ningning Wang

DOI: https://doi.org/10.1002/btm2.10728

2024-11-09

Bioengineering & Translational Medicine

Abstract:To review the theoretical basis and therapeutic effects of fecal microbiota transplantation (FMT) in various diseases in animal experiments and clinical studies, as well as the limitations and current standards of FMT application. PubMed and Web of Science databases were searched for articles published only in English between 1975 and 2023 on reliable results of animal experiments and clinical treatment of FMT. The properties of the gut microbiota and its interactions with the host metabolism are critical to human health, and microbiome disturbance is closely associated with human intestinal and extra‐intestinal diseases. Therefore, therapeutic tools targeting on the modulation of gut microbiota have attracted increasing attention, among which FMT represents the most widely studied intervention strategy. This review gathered and summarized application of FMT in intestinal diseases, metabolic diseases, hypertension, cancer, nervous system diseases and arthritis, and elaborated the beneficial effects that can be achieved by altering the microbiota with FMT and the mechanisms of action. In addition, the potential risks and side effects of FMT approach are discussed, as well as current efforts to standardize the development of FMT. Through a systemic review of the outcome and mechanism of FMT in the treatment of intestinal diseases and extra‐intestinal diseases, we aimed to provide a theoretical basis for the construction of an optimized FMT framework, so as to better exert its application prospects.

engineering, biomedical
Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE)

Siew C. Ng,Michael A. Kamm,Yun Kit Yeoh,Paul K. S. Chan,Tao Zuo,Whitney Tang,Ajit Sood,Akira Andoh,Naoki Ohmiya,Yongjian Zhou,Choon Jin Ooi,Varocha Mahachai,Chun-Ying Wu,Faming Zhang,Kentaro Sugano,Francis K. L. Chan

DOI: https://doi.org/10.1136/gutjnl-2019-319407

IF: 24.5

2020-01-01

Gut

Abstract:Objective The underlying microbial basis, predictors of therapeutic outcome and active constituent(s) of faecal microbiota transplantation (FMT) mediating benefit remain unknown. An international panel of experts presented key elements that will shape forthcoming FMT research and practice. Design Systematic search was performed, FMT literature was critically appraised and a 1-day round-table discussion was conducted to derive expert consensus on key issues in FMT research. Results 16 experts convened and discussed five questions regarding (1) the role of donor and recipient microbial (bacteria, viruses, fungi) parameters in FMT; (2) methods to assess microbiota alterations; (3) concept of keystone species and microbial predictors of FMT, (4) influence of recipient profile and antibiotics pretreatment on FMT engraftment and maintenance and (5) new developments in FMT formulations and delivery. The panel considered that variable outcomes of FMT relate to compositional and functional differences in recipient's microbiota, and likely donor-associated and recipient-associated physiological and genetic factors. Taxonomic composition of donor intestinal microbiota may influence the efficacy of FMT in recurrent Clostridioides difficile infections and UC. FMT not only alters bacteria composition but also establishes trans-kingdom equilibrium between gut fungi, viruses and bacteria to promote the recovery of microbial homeostasis. FMT is not a one size fits all and studies are required to identify microbial components that have specific effects in patients with different diseases. Conclusion FMT requires optimisation before their therapeutic promise can be evaluated for different diseases. This summary will guide future directions and priorities in advancement of the science and practice of FMT.
Fecal microbiota transplantation: History, procedure and regulatory considerations

Thanush D,M P Venkatesh

DOI: https://doi.org/10.1016/j.lpm.2023.104204

Abstract:Fecal microbiota transplantation (FMT) is a medical treatment which involves the transfer of feces from a healthy donor to a recipient to restore the balance of gut microbiota and improve clinical outcomes. FMT has gained recognition in recent years due to its effectiveness in treating recurrent Clostridioides difficile infections (rCDI) and other gastrointestinal disorders. Additionally, it has been studied as an intervention for some other conditions, like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). This review covers regulatory considerations related to FMT, including the current state of FMT regulation and the need for further research to fully understand the safety and efficacy of this treatment. For transplantation of fecal microbiota, the Food and Drug Administration (FDA) classifies the treatment as an investigational new drug (IND), which typically requires physicians and scientists to submit an IND application. Ethical issues surrounding FMT, including the necessity of informed consent from donors and recipients and the potential transmission of infectious agents, are also discussed. Overall, FMT has the potential to offer significant therapeutic benefits, but it also raises regulatory and ethical considerations that require careful consideration. Further research is necessary to fully comprehend risks and benefits of FMT and to develop guidelines for its use in clinical practice.
[Fecal Microbiota Transplants in the Context of (Child and Adolescent) Psychiatric Disorders]

Stefanie Trinh,Lara Keller,Beate Herpertz-Dahlmann,Jochen Seitz

DOI: https://doi.org/10.1024/1422-4917/a000928

Abstract:Fecal Microbiota Transplants in the Context of (Child and Adolescent) Psychiatric Disorders Abstract: There has recently been a significant increase in interest in gut microbiota and its interaction with the brain (gut-brain axis). Not only are the findings of microbiome research interesting for basic scientists, they also offer relevant insights for clinical practice. A causal relationship between gut microbiome and various somatic diseases such as diabetes mellitus, inflammatory bowel diseases, and obesity as well as psychiatric diseases such as major depression, anxiety disorders, and eating disorders seems plausible. To study the causal relationship of intestinal bacteria with individual phenotypes, researchers apply so-called stool transplantations (fecal microbiota transplantations) in the preclinical context. For this purpose, they transfer microbiota samples from patients into laboratory animals to observe possible changes in phenotype. In the clinical context, fecal microbiota transplantation is already being used with therapeutic intentions for selected diseases, for example, recurrent infections with Clostridioides difficile or inflammatory bowel diseases; they have already become part of the official clinical guidelines for C. difficile. For many other diseases, however, including mental illnesses, the potential of using fecal transplantations for therapeutic purposes is still being explored. Previous findings suggest that the intestinal microbiome, particularly fecal microbiota transplantations, represent a promising starting point for new therapeutic approaches.
Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation

Sergii Tkach,Andrii Dorofeyev,Iurii Kuzenko,Nadiya Boyko,Tetyana Falalyeyeva,Luigi Boccuto,Emidio Scarpellini,Nazarii Kobyliak,Ludovico Abenavoli

DOI: https://doi.org/10.3390/medicina58010084

2022-01-06

Medicina

Abstract:The intestinal microbiota plays an important role in maintaining human health, and its alteration is now associated with the development of various gastrointestinal (ulcerative colitis, irritable bowel syndrome, constipation, etc.) and extraintestinal diseases, such as cancer, metabolic syndrome, neuropsychiatric diseases. In this context, it is not surprising that gut microbiota modification methods may constitute a therapy whose potential has not yet been fully investigated. In this regard, the most interesting method is thought to be fecal microbiota transplantation, which consists of the simultaneous replacement of the intestinal microbiota of a sick recipient with fecal material from a healthy donor. This review summarizes the most interesting findings on the application of fecal microbiota transplantation in gastrointestinal and extraintestinal pathologies.

Fecal microbiota transplantation in childhood: past, present, and future

Fecal microbiota transplantation: current challenges and future landscapes

Faecal microbiota transplantation in children: A systematic review

What nurses need to know about fecal microbiota transplantation: education, assessment, and care for children and young adults

Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook

Fecal Microbiota Transplantation: An Update on Clinical Practice

Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives

Fecal microbiota transplantation: in perspective

An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases

Fecal microbiota transplantation and emerging applications

Clinical Application and Potential of Fecal Microbiota Transplantation

Long-term safety and efficacy of fecal microbiota transplantation in 74 children: A single-center retrospective study

Fecal Microbiota Transplantation in Treatment of Inflammatory Bowel Disease in Children

Fecal Microbiota Transplantation: Indications, Methods, and Challenges

Systematic Review: Faecal Microbiota Transplantation Therapy for Digestive and Nondigestive Disorders in Adults and Children

Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Fecal microbiota transplantation for the treatment of intestinal and extra‐intestinal diseases: Mechanism basis, clinical application, and potential prospect

Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE)

Fecal microbiota transplantation: History, procedure and regulatory considerations

[Fecal Microbiota Transplants in the Context of (Child and Adolescent) Psychiatric Disorders]

Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation